PfizerPFE
Recorded

Pfizer 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 12 minParticipants18

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good day, everyone, and welcome to Pfizer's Third Quarter 2026 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President.

Francesca DeMartinoChief Investor Relations Officer and SVP

Please go ahead, ma'am. Good morning, and welcome to Pfizer's earnings call.

Francesca DeMartinoChief Investor Relations Officer and SVP

I'm Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com. Earlier this morning, we released our results for the third quarter 2026 via a press release that is available on our website at pfizer.com. I'm joined today by Dr. Albert Bourla, our Chairman and CEO, Cecile Guegan, our CFO, and Chris Boshoff, our Chief Scientific Officer. After their prepared remarks, we will open the call for questions. Members of our leadership team will be available for the Q&A session. Before we get started, I want to remind you that we will be making forward-looking statements and discussing certain non-GAAP financial measures.

Francesca DeMartinoChief Investor Relations Officer and SVP

I encourage you to read the disclaimers in our slide presentation, the press release we issued this morning, and the disclosures in our SEC filings, which are all available on the IR website on pfizer.com. Forward-looking statements on the call are subject to substantial risks and uncertainty, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements. With that, I will turn the call over to Albert.

Albert BourlaChairman and CEO

Thank you, Francesca. Good morning, everyone, and thank you for joining our call. I'm pleased with another strong quarter for Pfizer. Our excellent commercial execution, including 32% operational revenue growth in the quarter for our launched and acquired products, shows the underlying strength of our business. Financial discipline and ongoing productivity improvement are driving efficiency and contributing favorably toward our margins. With continued progress of our high-value R&D programs, we believe that we are on a pathway to the next stage of meaningful growth. Before going further, I want to welcome Cécile Guegan as our Chief Financial Officer. Cécile brings more than 25 years of finance leadership and the proven ability to deliver new sources of growth.

Albert BourlaChairman and CEO

She stood out in a global search for her expertise, her deep knowledge of Pfizer and our industry, and the strategic vision that I believe will help Pfizer unlock sustained long-term value for patients and shareholders. I'm looking forward to Cécile's partnership, and I'm confident she will help us execute with the discipline and ambition this next chapter requires. Now, let me cover several highlights of our progress in this quarter. As you know, over the last few years, we have invested close to $80 billion in transactions that have equipped us with key products, contributing to current commercial momentum and platforms with transformative potential. About 80% of this investment was for Seagen, Metsera, and Biohaven, and we are making good progress in maximizing the value of each one. We are pleased with the overall performance of our acquired products, which grew 37% operationally in this quarter.

Albert BourlaChairman and CEO

Our legacy Seagen portfolio grew 39% year over year in the U.S. in the quarter, driven by the strong performance of PADCEV. Bringing Seagen's medicines together with the strength and reach of our commercial organization has deepened our presence in the oncology community. We now offer physicians and care teams a broader set of options and more expertise, helping patients and driving growth for Pfizer. Seagen did more than strengthen our commercial position. It also expanded our ability to discover oncology breakthroughs, doubling the size of our early-stage pipeline at the time we closed the acquisition. In our late-stage development programs, we are advancing potential antibody drug conjugates that could bring meaningful improvements for patients with cancer. I'm pleased with the pace of progress over the past year with our expansive clinical development program across our obesity portfolio.

Albert BourlaChairman and CEO

We plan to advance 10 active and planned phase III trials in 2026, including one evaluating a switch from approved weekly therapies to our investigational monthly GLP-1 peptide, berobenatide. We have made significant progress with enrollment across our pivotal berobenatide program, as well as our amylin combination program, where our phase IIb study is now fully enrolled. We are working toward the first in a series of potential approvals for berobenatide in 2028, with planning of our go-to-market strategy well underway. Biohaven also has been a strategically important addition for Pfizer. In the quarter, NURTEC grew by 33% operationally, driven by underlying demand and excellent commercial execution. We see real opportunity to help patients with migraine and for the oral CGRP class to be a key growth driver, even as we manage market dynamics in a competitive field.

Albert BourlaChairman and CEO

We are leading the oral CGRP class in the U.S. and are working to extend that position internationally. We are seeing international growth as more patients can now get this treatment in key countries, including the U.K., Italy, and Japan. We are also encouraged by strong adoption when we are able to expand access. 2026 execution in R&D has been strong, and we continue to prioritize the highest value opportunities for patients and future growth across our four therapeutic focus areas. Our excellent progress showcases our momentum in advancing our strategy. In recent months, we achieved two key regulatory decisions, one key pivotal readout, and eight key pivotal study starts, alongside strong data we presented at several recent medical congresses. We are excited by the pipeline opportunities in areas of strategic focus and commercial strength.

Albert BourlaChairman and CEO

This includes late-stage programs across tumor types in oncology, including multiple myeloma, breast cancer, and lung cancer, within inflammation and immunology, and of course, in pneumococcal vaccines. Chris will share more detail about our recent advancement in the recent months. Our pipeline strategy is grounded in disciplined prioritization and accelerated execution, and we are confident that we are advancing our most significant opportunities for future patient impact and growth. Today, we are raising our guidance for full year 2026 revenue and adjusted earnings per share. This reflects our strong performance through the third quarter and confidence in our ability to execute our strategy. Along with our financial discipline and the progress we continue to make with our R&D pipeline, we believe Pfizer is well-positioned to drive growth toward the end of the decade and create sustained value for patients and shareholders over the long term.

Albert BourlaChairman and CEO

We have deployed AI in our business with the goal of improving efficiency in manufacturing and sharpening how we engage physicians and patients. In R&D, we are working to accelerate innovation with faster target validation and better molecule and biomarker selection. The recent launch of GENESIS, a new pharmacovigilance platform, shows our commitment to harnessing advanced AI and intelligent automation for global safety monitoring. This typically involves a lengthy manual process for more than 600 products in over 120 countries. GENESIS takes on the administrative burden so our safety scientists can spend their time where it matters most: assessing causality, detecting safety signals, and protecting patients. With that, I will turn it over to Cécile.

Cecile GueganCFO

Thank you, Albert, and good morning. I am proud to speak to you today as Pfizer's CFO. I am looking forward to continuing to work alongside the executive leadership team and lead our world-class finance organization. I am genuinely excited about what we can achieve together, and I will approach this role with financial discipline and a focus on translating Pfizer's scientific and commercial progress into durable shareholder value. I am confident in our strategy and that as a team, we can deliver durable long-term value for our shareholders with rigorous capital allocation and disciplined execution. Now, I am pleased to share our third quarter results, which demonstrate continuous commercial execution and financial discipline. Revenues from our non-COVID product delivered solid growth, while product mix, productivity, and cost management supported margin expansion and enabled continuous investment across our robust pipeline.

Cecile GueganCFO

This year performance gives us the confidence to raise our full year 2026 revenue guidance, as well as raise and narrow our adjusted diluted EPS guidance. Now, onto the results. Third quarter 2026 revenue of $16.6 billion came in ahead of our expectation, with strong 7% operational revenue growth of our non-COVID products, driven by key brands in the U.S. and select international markets, offset by lower revenues from our COVID-19 products. On the bottom line, third quarter 2026 reported diluted EPS was $0.56. In addition, adjusted diluted EPS of $0.87 exceeded our expectation and includes the $0.10 charge related to the Innovent transaction. This outperformance reflects cost discipline and improved productivity across the organization, even as we increase investment towards future growth drivers and advance several phase III study starts.

Cecile GueganCFO

We saw solid revenue contributions in the quarter from ELIQUIS, PAXLOVID, the VYNDAQEL family, NURTEC, and LORBRENA. While our COVID-19 products and the PREVNAR family declined in the quarter. Our launched and acquired product contributed $3.8 billion in revenues and grew 32% operationally in the quarter, primarily driven by PADCEV, up $255 million, NURTEC, up $175 million, and LORBRENA, up $114 million. We continue to invest behind this group of products to mitigate LOE headwinds over the next several years. In addition, this quarter's performance demonstrates clear progress against our objective of returning to growth towards the end of the decade. Cost discipline and continued optimization across the company, including our manufacturing footprint, remain priorities.

Cecile GueganCFO

We are making meaningful progress with our productivity initiatives and remain on track to deliver nearly all of the anticipated $7.2 billion of net savings by the end of 2026 for our ongoing cost improvement programs. As we announced last quarter, we are initiating the next phase of these programs to deliver an anticipated additional $2.5 billion of net cost savings from 2027 through 2029. These savings support increased operating efficiency and contribute favorably to our margins. At the same time, we continue to prioritize investment in pipeline programs that we believe have the greatest potential to deliver meaningful breakthroughs for patients and create long-term value for our shareholders. Adjusted gross margin for the third quarter was 77%, primarily reflecting favorable product mix and continued cost management.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day